Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience-Reference-Cited by-同舟云学术

Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience

Published:2019-03 Issue:1 Volume:7 Page:25-29
ISSN:2287-8882
Container-title:Prostate International
language:en
Short-container-title:Prostate International

Author:

Costa Renato P.,Bordonaro Sebastiano^ORCID,Cappuccio Francesco^ORCID,Tripoli Vincenzo,Murabito Alessandra,Licari Maria,Valerio Maria R.,Tralongo Paolo

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Mechanisms of bone metastasis;Mundy;Cancer,1997

3. Factors regulating the growth of metastatic cancer in bone;Boyce;Endocr Relat Cancer,1999

4. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer;DePuy;Support Care Cancer,2007

5. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer;Weinfurt;Ann Oncol,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study;Minerva Urology and Nephrology;2023-01

2. Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis;Tumori Journal;2022-03-31

3. Optimierung der 223Radium-Dichlorid-Therapie von Patienten mit kastrationsresistentem Prostatakarzinom und Knochenmetastasen;best practice onkologie;2021-10-27

4. The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study;Journal of Experimental & Clinical Cancer Research;2021-09-06

5. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer;PLOS ONE;2021-06-21